All Patients | Univariate Analysis | Multivariate Regression Analysis | |||||
---|---|---|---|---|---|---|---|
No SDAI remission | SDAI remission | p value | OR (95% CI) | p value | |||
Number | 69 | 49 | 20 | ||||
Females† | 58 (84.1%) | 41 (83.7%) | 17 (85.0%) | 0.602 | |||
Age (years)* | 61.80 (52.54; 69.68) | 66.46 (58.62; 72.84) | 59.27 (47.54; 68.61) | 0.070 | per year increase | 1.01 (0.92; 1.11) | 0.782 |
Weight (kg)* | 63.00 (55.00; 77.50) | 63.50 (59.00; 79.75) | 56.00 (53.00; 74.50) | 0.574 | |||
Positive rheumatoid factor or anti-citrullinated peptides† | 46 (66.67%) | 35 (71.43%) | 11 (55.00%) | 0.151 | 0.59 (0.09; 3.92) | 0.586 | |
Disease duration (years)* | 17.08 (13.48; 25.27) | 17.47 (13.23; 22.71) | 16.51 (11.61; 31.38) | 0.963 | |||
ETN treatment duration (years)* | 9.50 (6.92; 11.05) | 8.70 (6.46; 11.02) | 9.68 (7.79; 11.42) | 0.667 | |||
Low-dose ETN duration (years)* | 6.74 (5.73; 8.70) | 6.35 (4.75; 8.48) | 8.14 (6.74; 9.05) | 0.031 | per year increase | 1.31 (0.89; 1.94) | 0.168 |
Full-dose Etanercept | 35 (50.7%) | 29 (59.2%) | 6 (30.0%) | 0.026 | 0.408 (1.06; 1.57) | 0.191 | |
Basal ETN serum levels (μg/mL)* | 2.22 (1.27; 3.36) | 1.32 (0.66; 2.47) | 1.48 (1.26; 1.98) | 0.781 | |||
Positive anti-ETN antibodies† | 1 (1.4%) | 1 (2.0%) | 0 (0%) | 0.710 | |||
High ETN level (≥3.1 μg/mL)† | 1.65 (1.00; 2.89) | 2.34 (1.24; 3.54) | 1.59 (1.28; 2.24) | 0.426 | |||
Concomitant MYX use† | 17 (%) | 13 (24.5%) | 4 (25.0%) | 0.603 | |||
Prednisone daily dose* | 2.50 (0.00; 5.00) | 2.50 (0.00; 3.63) | 0.50 (0.00; 2.50) | 0.338 | |||
HAQ* | 1.00 (0.60; 1.25) | 1.00 (0.75; 1.43) | 0.41 (0.24; 0.78) | <0.001 | per unit increase | 0.04 (0.00; 1.04) | 0.053 |
DAS28* | 2.11 (1.36; 2.35) | 2.23 (2.02; 2.47) | 1.10 (0.87; 1.15) | <0.001 |
*Median (interquartile range); †number (percentage).